周五开播 | 从JPM大会，看新的一年行业走向 _健康小知识

文章图片
JPMWebinarSeriesPresents
StartfromJPM,
seewherethemarketgoesin2023
阔别两年，全球瞩目的JPMorgan健康大会终于在2023年1月恢复了线下举行。作为全球生物制药、医疗投资领域规模最大的行业盛会，这一周将会汇集从世界各地奔赴而来的行业领导者，新兴快速增长公司、创新技术公司和全球投资者，在SanFrancisco开展业务发展和合作。
对全球生物制药来说，这是一年中最重要的一周，是窥探各家公司下一步动作和行业风向标的绝佳时刻。为此， bioSeedin邀请了正在旧金山参加JPMWEEK的中国KOL们，在大会结束之际谈谈本次JPM之旅的个人感受，预测和释放出一些积极信号。
北京时间|Beijing
10：00—11：30AM
1月13日（周五）上午
Jan.13(Fri.),2023
美西时间|PST
18:00-19:30PM
1月12日（周四）晚上
Jan.12(Thur.),2023
#议程
Agenda
01
开场|Opening
02
圆桌讨论|Panel
1.本次JPM之旅整体感受如何？行业景气度中美产业区别哪类企业不缺钱？哪类企业最缺钱？监管政策层面今年最大的变化等
2.印象最深企业是哪一家？为什么？
3.您所从事的领域哪个产品或者技术今年有可能成为明星？为什么？
4.预测下您关注的领域中2023年行业整体走向哪些方面值得关注？
1.OverviewofthisJPMHowabouttheindustryprosperity?DifferencesbetweenChinaandtheUnitedStates？Whichtypeofenterpriseshasthemostsufficientfunds?Whichtypeisshortofmoney?Thebiggestchangeinregulatorypolicythisyear
2.Whichcompanyimpressedyoumost?Why?
3.Whichproductortechnologyinyourfieldislikelytobecomeastarthisyear?Why?
4.In2023,whattrendsoftheindustryinyourareasofconcernareworthpayingattentionto?
嘉宾|SPEAKERS

文章图片
吴振华博士
ZhenhuaWu,Ph.D
嘉因生物科技
ExegenesisBio
创始人及CEO
Co-founder&CEO
Dr.ZhenhuaWuistheFounder,ChairmanandChiefExecutiveOfficerofExegenesisBio.Dr.Wuisaseniordiscoveryanddevelopmentleaderwithmorethan20years’experienceandadeepunderstandingofpharmaceuticalR&Dvaluechain.HehasextensiveR&Dexperienceinsmallmolecule,vaccineandcellandgenetherapy.Dr.WuwastheCEOofNeuExcellTherapeutics,overseeingallcorporateoperationsandbusinessactivities.
PreviouslyhewastheVicePresident,HeadofPreclinicalDevelopmentatUnitedNeuroscience,andoversawthestrategyandexecutionofpreclinicalresearchanddevelopment.HeservedasadirectorofneurosciencetherapeuticareaatGlaxoSmithKline,whereheledcellandgenetherapyandsmallmoleculeprojectsforthetreatmentofneurodegenerativeandneuroinflammatorydiseases.
HehadworkedinvariousfunctionalareasinMerck&Co.fortenyearswhereheledvariousneuroscienceprojects.Dr.WureceivedhisPh.D.degreeinneurosciencefromUniversityofRochester.

文章图片
汪文博士
WenWang,MD,Ph.D
驯鹿生物
IASOBiotherapeutics
首席执行官CEO
Dr.WangjoinedIASOBiotherapeuticsinMarch2020,andiscurrentlythecompany’sChiefExecutiveOfficer.
Dr.WanggraduatedfromAnhuiMedicalUniversitywithaBachelorofMedicine(B.M.)degree.HewasanorthopedicresidentdoctorandattendingphysicianinShanghaiTCMIntegratedHospital.Dr.WangsubsequentlyobtainedMasterofMedicine(M.M.)degreefromTongjiUniversityandDoctorofMedicine(M.D.)degreefromTongjiUniversity/Universit?tWürzburg,aswellasdoctorateinmolecularbiology(Ph.D.)fromUniversityofAberdeen.Hewasapost-doctoralfellowintheUniversityofConnecticutHealthCenter,duringwhichhepublishedover20papersinSCI-indexedjournalsoncelltherapiesinleadingpublicationsincludingClinicalCancerResearchandBlood.
Dr.Wangjoinedthepharmaindustryin2013,havingworkedwithCellularBiomedicineGroup(NASDAQ:CBMG),JWTherapeutics(HKEX:02126),andSimecerePharmaceuticalGroup(SEHK:02096)asMedicalDirector,HeadofClinicalDevelopmentandHeadofClinicalSciences,respectively.